Caribou Biosciences is developing CRISPR technologies to create allogeneic cell therapies for oncology. Caribou has built CRISPR hybrid RNA-DNA (chRDNA), their proprietary technology that enables highly efficient, highly specific genome editing. chRDNA is then used to develop sophisticated genome-edited cell therapies. For example, Caribou is using chRDNA to create next-generation allogeneic CAR-T and CAR-NK cell therapies to enhance the longevity and persistence of the cells. Scientific advances have been published in high-impact journals. Caribou has one ongoing Phase I clinical trial to evaluate CB-010 in adults with relapsed B cell non-Hodgkin lymphoma.

<p>Caribou Biosciences is developing CRISPR technologies to create allogeneic cell therapies for oncology. Caribou has built CRISPR hybrid RNA-DNA (chRDNA), their proprietary technology that enables highly efficient, highly specific genome editing. chRDNA is then used to develop sophisticated genome-edited cell therapies. For example, Caribou is using chRDNA to create next-generation allogeneic CAR-T and CAR-NK cell therapies to enhance the longevity and persistence of the cells. Scientific advances have been published in high-impact journals. Caribou has one ongoing Phase I clinical trial to evaluate CB-010 in adults with relapsed B cell non-Hodgkin lymphoma.</p>


Caribou Biosciences

Short description:

Drug notes:

Long description:

Jobs: